Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate

Joint Bone Spine

Volumn 72, Issue 1, 2005, Pages 48-52

  Sellam, Jérémie ^a   Allanore, Yannick ^a   Batteux, Frédéric ^a   Deslandre, Chantal Job ^a   Weill, Bernard ^a   Kahan, André ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Autoantibodies; Infliximab; Methotrexate; Spondyloarthropathies

Indexed keywords

AUTOANTIBODY; CELL NUCLEUS ANTIGEN; DOUBLE STRANDED DNA; HISTONE; HISTONE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; INFECTION; MALE; SIDE EFFECT; SPONDYLOARTHROPATHY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; SPONDYLARTHROPATHIES;

EID: 12844270059     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2004.03.003     Document Type: Article

References (28)

1. Saraux A., Guedes C., Allain J., Devauchelle V., Valls I., Lamour A., et al. Société de Rhumatologie de l'Ouest. Prevalence of rheumatoid arthritis and spondylarthropathy in Brittany. France. J Rheumatol. 26:1999;2622-2627
2. Dougados M., van der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 38:1995;618-627
3. Clegg D.O., Reda D.J., Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs Cooperative study. Arthritis Rheum. 42:1999;2325-2329
4. Cuellar M.L., Espinoza L.R. Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am. 23:1997;797-809
5. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., et al. Use of immunohistologic and in situ hybridization techniques in the examination of the sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 38:1995;499-505
6. Van den Bosch F., Kruithof E., de Vos M., de Keyser F., Mielants H. Crohn's disease associated with spondylarthropathy: effect of TNF-α blockade with infliximab on the articular symptoms. Lancet. 356:2000;1821-1822
7. Breban M., Vignon E., Claudepierre P., Devauchelle V., Wendling D., Lespessailles E., et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a 6-month open-label study. Rheumatology. 41:2002;1280-1285
8. Van den Bosch F., Kruithof E., Baeten D., De Kayser F., Mielants H., Veys E.M. Effects of a loading dose regimen of anti-tumour necrosis factor alpha (infliximab) in spondylarthropathy: an open pilot study. Ann Rheum Dis. 59:2000;428-433
9. Brandt J., Haibel H., Cornely D., Golder W., Gonzalez J., Redding J., et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum. 43:2000;1346-1352
10. Van den Bosch F., Kruithof E., Baeten D., Herssens A., De Kayser F., Mielants H., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 46:2002;755-765
11. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 359:2002;1187-1193
12. Provenzano G., Termini A., Le Moli C., Rinaldi F. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease-modifying antirheumatic drugs: an open pilot study. Ann Rheum Dis. 62:2003;680-681
13. Brandt J., Khariouzov A., Listing J., Haibel H., Sorensen H., Grassnickel L., et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 48:2003;1667-1675
14. Centocor, Inc. Remicade (infliximab). Data on file.
15. De Rycke L., Kruithof E., Van Damme N., Hoffman I.E., Van den Bossche N., Van den Bosch F., et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 48:2003;1015-1023
16. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthtritis Rheum. 41:1998;1552-1563
17. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., et al. for the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 34:1991;1218-1227
18. Preud'homme J.L., Rochard E., Gouet D., Danon F., Alcalay M., Touchard G., et al. Isotypic distribution of anti-double-stranded DNA antibodies: a diagnostic evaluation by enzyme-linked immunosorbent assay. Diagn Clin Immunol. 5:1988;256-261
19. Rubin R.L. Enzyme-linked immunosorbent assays for antibodies to native DNA, histones and (H2A-H2B)-DNA. Rose N.R., de Macario C., Folds J.D., Cliford L.H., Nakamura R.M. Manual of clinical laboratory immunology. 1997;935-941 ASM Press, Washington, DC
20. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43:2000;2383-2390
21. Immunex Corp. Enbrel (etanercept). Data on file.
22. Shakoor N., Michalska M., Harris C.A., Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 359:2002;579-580
23. De Dandt M., Descamps V., Meyer O. Two cases of entanercept-induced systemic lupus erythematous in patients with rheumatoid arthritis (abstract). Ann Rheum Dis. 60:2001;175
24. Bleumink G.S., ter Borg E.J., Ramselaar C.G., Ch Stricker B.H. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford). 40:2001;1317-1319
25. Misery L., Perrot J.L., Gentil-Perret A., Pallot-Prades B., Cambazard F., Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol. 146:2002;334-335
26. Markham A., Harriet M.L. Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs. 59:2000;1341-1359
27. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 121:2001;1145-1157
28. Trebeden-Negre H., Weill B., Fournier C., Batteux F. B cell apoptosis accelerates the onset of murine lupus. Eur J Immunol. 33:2003;1603-1612